CUSIP: 87424L207
Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
789,494
-
Share change
-
-3,032
-
Total reported value
-
$6,842,021
-
Price per share
-
$8.66
-
Number of holders
-
18
-
Value change
-
-$26,793
-
Number of buys
-
4
-
Number of sells
-
8
Quarterly Holders Quick Answers
What is CUSIP 87424L207?
CUSIP 87424L207 identifies TLIS - TALIS BIOMEDICAL CORP - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2024
-
Previous quarter:
Q1 2024
Recent filing periods for CUSIP 87424L207:
Institutional Holders of TALIS BIOMEDICAL CORP - COM NEW (TLIS) as of Q2 2024
As of 30 Jun 2024,
TALIS BIOMEDICAL CORP - COM NEW (TLIS) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
789,494 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, DME Capital Management, LP, BML Capital Management, LLC, VANGUARD GROUP INC, PRELUDE CAPITAL MANAGEMENT, LLC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, BlackRock Inc., and Tower Research Capital LLC (TRC).
This page lists
18
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.